
Pulmonx (LUNG) Stock Forecast & Price Target
Pulmonx (LUNG) Analyst Ratings
Bulls say
Pulmonx Corp has demonstrated a strong financial trajectory, achieving total revenue of $83.8 million for the full year 2024, marking a 22% increase from 2023, underpinned by robust domestic sales and significant international growth. The company's strategic advancements in technology, such as the Chartis Pulmonary Assessment System, alongside expanded reimbursement coverage, are expected to drive broader adoption of its innovative treatments, enhancing market potential. Additionally, the record worldwide revenue of $23.8 million in Q4 2024, a 23% year-over-year increase, reflects growing confidence among physicians and sustained adoption of Pulmonx's solutions in clinical practice.
Bears say
Pulmonx Corp reported a gross profit of $17.6 million for the quarter, with a slight decline in gross margin to 74%, down from 75% in the previous quarter, indicating potential challenges in maintaining profitability. The company also experienced a decrease in cash reserves, with cash, cash equivalents, and marketable securities falling to $101.5 million from $107.8 million, raising concerns about its liquidity and financial stability. Additionally, as a small capital company, Pulmonx faces inherent volatility and risk, compounded by the growing incidences of COPD in aging populations, which may limit its market expansion capabilities and heighten competitive pressures.
This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.
Pulmonx (LUNG) Analyst Forecast & Price Prediction
Start investing in Pulmonx (LUNG)
Order type
Buy in
Order amount
Est. shares
0 shares